Universität zu Köln

Vergote, I, Gonzalez-Martin, A., Ray-Coquard, I, Harter, P., Colombo, N., Pujol, P., Lorusso, D., Mirza, M. R., Brasiuniene, B., Madry, R., Brenton, J. D., Ausems, M. G. E. M., Buettner, R. and Lambrechts, D. (2022). European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann. Oncol., 33 (3). S. 276 - 288. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Full text not available from this repository.

Abstract

Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. Design: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts' consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. Conclusion: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR deficiency testing for recently diagnosed patients with advanced ovarian cancer.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Vergote, I UNSPECIFIED UNSPECIFIED UNSPECIFIED Gonzalez-Martin, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ray-Coquard, I UNSPECIFIED UNSPECIFIED UNSPECIFIED Harter, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Colombo, N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pujol, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lorusso, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mirza, M. R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brasiuniene, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Madry, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brenton, J. D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ausems, M. G. E. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Buettner, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lambrechts, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-696596
DOI:	10.1016/j.annonc.2021.11.013
Journal or Publication Title:	Ann. Oncol.
Volume:	33
Number:	3
Page Range:	S. 276 - 288
Date:	2022
Publisher:	ELSEVIER
Place of Publication:	AMSTERDAM
ISSN:	1569-8041
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MISMATCH REPAIR DEFICIENCY; OLAPARIB PLUS BEVACIZUMAB; SOMATIC MUTATIONS; BRCA2 MUTATIONS; MAINTENANCE THERAPY; GERMLINE MUTATIONS; FALLOPIAN-TUBE; DOUBLE-BLIND; CARCINOMA; BREAST Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69659